The first such trial evaluated single-agent anti-CTLA-4 ipilimumab (10 mg/kg given every 3 weeks for four doses, followed by 10 mg/kg every 12 weeks) in melanoma BM patients (NCT00623766) [3]. This evidence concerns the gene CTLA4 and melanoma.